Elisabeth I. Heath
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (106)
A and B. Evaluation of Vβ repertoire. The three distinct patterns were observed for Vβ repertoire in CD3+/IFN-γ+ T cells post IT. Pattern 1) the proportions of Vβ repertoire noticeably higher after IT relative to preIT PBMC (solid black arrows); Pattern 2) the proportions of Vβ repertoire that were marginally higher at mid- and/or post-IT relative to pre-IT PBMC (dashed black arrows); Pattern 3) large proportions of Vβ repertoire were either lower or similar at mid-IT or post-IT relative to preIT PBMC in all four patients tested. PreIT (pretherapy), midIT (preinfusion 5) postIT (1 week post infusion 8 of BATs).
Year:
2025
A-C. FFPE sections of PC were stained by multiplex staining panel for CD4, CD8, FoxP3 (T regulatory cells), CD19 (B cells), CD68 (macrophages). Stained sections were imaged on the Hamamatsu slide scanner NanoZoomer S360 and images were viewed on the NDP viewer software. Analysis of images were performed on online Visiopharm software. Using the low power image, high-powered Fields (HPFs) were selected from specific tumor regions. Data shows the distribution of CD4+ (teal), CD8+ (purple), FoxP3 (brown), CD19+ (green) and CD68+ (yellow) cells on two representative whole scanned slide images (KCI 04 and KCI 11) are shown. Top panel shows whole scanned tumor sections, inset 1 and 2 are shown below at high magnification (40x). B and C) Show the second set of serial sections of tumor specimens stained for IFN-γ and IL-10 from two patients shown in the upper panel, both IFN-γ (brown) and IL-10 (brown) were stained individually.
Year:
2025
Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).
Year:
2025
The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors. Significance: This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.
Year:
2025
Supplemental Table 1 shows specimens by cancer type; Supplemental Figure 1 shows CH variants by patient age; Supplemental Figure 2 shows variant classification by gDNA and plasma variant frequency for gDNA VF ≤ 0.20
Year:
2025
Purpose: Plasma-based liquid biopsy tests can detect tumor-specific genetic alterations and offer many advantages that complement tissue-based comprehensive genomic profiling. However, age-related clonal hematopoiesis (CH) mutations can confound liquid biopsy results and potentially lead to incorrect therapy choice. Experimental Design: We assessed the landscape of 16,812 liquid profiles across 49 cancer types using the Caris Assure assay, a whole-exome and whole-transcriptome next-generation sequencing workflow that independently sequences both plasma-derived cell-free total nucleic acids and the white blood cell DNA and RNA from the buffy coat. The variant source was identified algorithmically by comparing plasma and buffy coat variant frequency and read quality metrics. Results: Of 16,812 patients, 42.3% presented at least one CH variant among reportable clinical genes. We found 39% of BRCA2 variants to be of CH origin, as well as 37.9% of CHEK2 , 27.4% of BRCA1 , 20.1% of ATM , 7.3% of NRAS , 5.8% of BRAF , 2.1% of EGFR , 2.1% of KRAS , and 18.5% of TP53 . For patients aged 65 to 69 years, the median proportion of CH variant classification was 20%, whereas it was 33% for patients aged 70 to 74 years, 33% for ages 75 to 79 years, and 50% for ages 80+ years. We found high rates of CH detected in what would be otherwise druggable targets in many cancer types typically treated with PARP inhibitors, including breast, female genital tract, ovarian, pancreatic, prostate, and endometrial cancers. Conclusions: This large study highlights the need for thorough CH classification during liquid biopsy to appropriately recommend therapies, especially PARP inhibitors. See related commentary by Bernard and Micol, p. 2545
Year:
2025
Supplementary Figure S3: Immune repertoire of DLL3-high versus –low NENs across anatomic sites. Stacked radar plots comparing the imputed cell fractions of immune cells between DLL3-high and -low samples in (A) lung NECs, (B) lung NETs, (C) prostate NENs, and (D) bladder NENs. *q
Year:
2025
Supplementary Figure S2: Correlations between expression of DLL3, ASCL1, and NEUROD1 across select NEN sites. Scatterplots displaying the expression of DLL3 vs ASCL1 (top) and DLL3 vs NEUROD1 (bottom) across NEN sites. Expression is depicted as log(TPM + 0.001). Spearman correlations and corresponding p-values are shown for each site.
Year:
2025
Supplementary Figure S1: UMAP view of NEN samples across diverse anatomic sites. Samples were unbiasedly clustered based off the top 1,000 variably expressed genes across samples and annotated using (A) DLL3 expression level and (B) anatomic site of origin.
Year:
2025
Supplementary Figure S4: Genetic dependencies in neuroendocrine cancer cell lines. Scatterplot displaying gene depletion effects in NEN lines represented in DepMap. Data points represent the mean gene depletion effect of each gene target. Highlighted genes represent potential dependencies (gene effect
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (103)
Greg Dyson
Professor
Wayne State University
Aditya Bagrodia
University of Texas Southwestern
Andrew Armstrong
Professor
Duke Cancer Institute
Yong Tae Kwon
Professor
Seoul National University
Ulka Vaishampayan
Professor
University of Michigan
Oliver Sartor
Tulane University School of Medicine
Guru P. Sonpavde
University of Central Florida
Ginger Milne
Professor with Tenure
Vanderbilt University Medical Center
Pedro Barata
Associate Professor of Medicine
University Hospitals Seidman Cancer Center
John Lozada
University of Rochester Medical Center
Benedito A. Carneiro
-
George Sledge
-
Grace Blitzer
University of Wisconsin-Madison
Frank Cackowski
Assistant Professor
Karmanos Cancer Institute
Samuel Kareff
University of Miami School of Medicine
Phillip Palmbos
Assistant Professor
University of Michigan Hospital
Hirva Mamdani
Karmanos Cancer Institute
Michael Brown
Assistant Professor
Duke University
Channing Paller
Johns Hopkins University
Joshua Lang
Professor
University of Wisconsin-Madison
Natalie Reizine
Assistant Professor
University of Chicago
Arul M Chinnaiyan
University of Michigan
Akhilesh Kumar
Faculty, Assistant Professor
University of Minnesota
Scott Tagawa
Weill Cornell Medicine
Emil Lou
University of Minnesota
Julie Boerner
Associate Professor
Wayne State University
Ari VanderWalde
Global Head of Clinical Trials
-
Young Whang
University of North Carolina at Chapel Hill School of Medicine
Mohammed Al Hallak
Assistant Professor
Wayne State University School of Medicine
Eugene Shenderov
Associate Professor
Johns Hopkins University School of Medicine
Kent Mouw
Assistant Professor
Dana-Farber Cancer Institute
HAMID EMAMEKHOO
University of Wisconsin-Madison
Justin E. Wilson
Associate Professor
-
Haojie Huang
Professor
Mayo Clinic College of Medicine and Science
Alicia Morgans
Dana-Farber Cancer Institute
Steven Kregel
Assistant Professor
Loyola University Chicago
Hyeong‐Reh C. Kim
Vice Dean of Research
Wayne State University
Justin Hwang
Associate Professor
University of Minnesota
Shuang G. Zhao
University of Wisconsin-Madison
Terry Hyslop
Professor, Director of SKCCC Center for Cancer Health Equity
Thomas Jefferson University
Kim Chi
Chief Medical Officer
BC Cancer
Veronica Rodriguez-Bravo
Associate Professor
Mayo Clinic
Shijia Zhu
Assistant Professor
University of Minnesota
Catherine Marshall
Associate Professor
Johns Hopkins University School of Medicine
Jinhua Wang
professor
University of Minnesota System
Wei Chen
Professor
Wayne State University
Lawrence G. Lum
Professor of Medicine
University of Virginia
Rohan Garje
Clinical Associate professor
Iowa State University
Daniel J. George
Professor
Duke University
Ira Winer
Professor
Wayne State University
David Hsiehchen
University of Texas Southwestern Medical Center
Frank Cichocki
Assistant Professor
University of Minnesota
Heloisa Soares
Associate Professor
Huntsman Cancer Institute
David Kosoff
University of Wisconsin-Madison
Noel Warfel
Associate Professor
Medical University of South Carolina
Emily Egusa
University of California, San Francisco
Josep Domingo-Domenech
Professor
Mayo Clinic
Heather H. Cheng
Professor
University of Washington
Menggang Yu
Professor
University of Michigan
Joaquin Mateo
Group Leader
Vall d´Hebron Institute of Oncology
Leonard Appleman
Associate Professor
University of Pittsburgh
Haidong Dong
Professor/Consultant
Mayo Clinic Rochester
Jacob Orme
Assistant Professor
Mayo Clinic
Scott M Dehm
Faculty, Professor
University of Minnesota
Abdo Najy
Assistant Professor-Research
Wayne State University
Evan Y. Yu
University of Washington
Marina N Sharifi
Assistant Professor
University of Wisconsin-Madison
Karen S Sfanos
Johns Hopkins University School of Medicine
Christopher J. Hoimes
Duke University
Anders Bjartell
Lund University
Anne Cress
Professor
University of Arizona
Emmanuel S. Antonarakis
-
Michael Carducci
Vice Chair, Solid Tumor Oncology
Johns Hopkins University
Carly Miller
University of Minnesota
Jonathan Chou
Assistant Professor
University of California, San Francisco
Jeffrey S Miller
University of Minnesota System
Felix Y. Feng
University of California
Mukesh Pandey
Professor of Radiology
Mayo Clinic
Atish Choudhury
Dana-Farber Cancer Institute
Archana Thakur
Associate Professor
University of Virginia
Kevin Kelly
Professor, Associate Director of Research, SKCC
Thomas Jefferson University
Shailender Singh Chauhan
Staff Scientist II
Medical University of South Carolina
Seongho Kim
Professor of Biostatistics
Wayne State University School of Medicine
Charles Nguyen
Assistant Clinical Professor
City Of Hope National Medical Center
Megan E.V. Caram
University of Michigan
Peter S. Nelson
Fred Hutchinson Cancer Research Center
Brent Rose
Associate Professor
UC San Diego Health System
Russell K. Pachynski
Washington University School of Medicine
Kathleen Storey
Assistant Professor
University of Minnesota
Nicholas Zorko
Assistant Professor
University of Minnesota
Neeraj Agarwal
Faculty Member
Dana-Farber Cancer Institute
Daniel P. Petrylak
-
Travis Wheeler
Professor
University of Arizona
Rana R. McKay
University of California, San Diego
Samuel R. Denmeade
-
Michael Gunn
Professor
Duke University
Dave Hoon
Principal Investigator
The Lundquist Institute
Yeon Sung Son
Research Professor
Seoul National University
Xiaolei Shi
Assistant professor
University of Maryland Medical Center
Amy Schienschang
University of Virginia
Veerabhadran Baladandayuthapani
Jeremy M.G. Taylor Collegiate Professor of Biostatistics and Chair of Department of Biostatistics
University of Michigan
Sebastien Hotte
McMaster University
Gilberto Lopes
Associate Professor
Sylvester Comprehensive Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.